Insider Trading History of Lin Shao-lee

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Lin Shao-lee since 2019. This trader's CIK number is 1725092. At the time of last reporting, Lin Shao-lee was the Chief Executive Officer of Acelyrin, Inc.. (stock ticker symbol SLRN). Also see all insider trading activities at Acelyrin, Inc..

Note that in the past Lin Shao-Lee also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Acelyrin, Inc. (SLRN) by Lin Shao-lee

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 SLRN 0 $0 36,353 $264,615 0 $0

Yearly summary of insider trading at Horizon Therapeutics Public Ltd Co (HZNP) by Lin Shao-lee

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2020 HZNP 0 $0 0 $0 68,236 $0
2019 HZNP 0 $0 0 $0 50,253 $0


Insider trading activities at 2 companies by Lin Shao-lee:

1. Acelyrin, Inc. (SLRN)

2. Horizon Therapeutics Public Ltd Co (HZNP)

Table 1. Insider trading of Acelyrin, Inc. (SLRN) by Lin Shao-lee

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-04-01 SLRN Sale 9,961 6.63 66,021
2024-02-20 SLRN Sale 15,701 7.61 119,406
2024-01-02 SLRN Sale 10,691 7.41 79,188

Table 2. Insider trading of Horizon Therapeutics Public Ltd Co (HZNP) by Lin Shao-lee

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2020-01-05 HZNP Option Ex 50,344 .00 0
2020-01-04 HZNP Option Ex 17,892 .00 0
2019-01-05 HZNP Option Ex 32,362 .00 0
2019-01-04 HZNP Option Ex 17,891 .00 0

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lin Shao-lee (Chief Executive Officer of Acelyrin, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.